2800 Plymouth Rd, NCRC Bldg 16, Room 138E
Ann Arbor, MI 48109-2800
Available to mentor
-
PostDoctoral TrainingUniversity of Michigan–Ann Arbor, Urology, 2005
-
PostDoctoral TrainingUniversity of Michigan–Ann Arbor, Urology, 2004
-
PostDoctoral TrainingUniversity of Michigan–Ann Arbor, Urology, 2003
-
PostDoctoral TrainingUniversity of Michigan–Ann Arbor, Urology, 2002
-
PostDoctoral TrainingUniversity of Michigan–Ann Arbor, Ann Arbor, 1998
Dr. Hollenbeck's research examines how delivery system organization and incentives affect clinical practice. He has been generously supported by both career development and research scholar grants from the American Cancer Society. His ongoing research agenda is supported by numerous extramural agencies, including R01 funding from the Agency for Healthcare Research and Quality and the National Institute on Aging. Dr. Hollenbeck has written extensively on financial incentives, quality, and cost and their intersection with evolving delivery system reforms. Dovetailing with his research, Dr. Hollenbeck is deeply committed to mentoring young physicians who share his passion for clinical investigation and health services research. He has served as primary mentor for more than a dozen postdoctoral trainees, nearly all of who have successfully competed for extramural funding after finishing their training. Dr. Hollenbeck has been integrally
involved as co-investigator for the "first-of-its-kind" NIDDK T32 award aimed at training urologists in health services research. He is co-principal investigator of a T32 award supporting the scientific development of urologic oncologists, sponsored by the NCI.
-
Post B, Hollenbeck BK, Norton EC, Ryan AM. Health Serv Res, 2024 Feb; 59 (1): e14172Journal ArticleHospital-physician integration and clinical volume in traditional Medicare.
DOI:10.1111/1475-6773.14172 PMID: 37248765 -
Maganty A, Kaufman SR, Oerline MK, Faraj K, Caram MEV, Shahinian VB, Hollenbeck BK. Urol Pract, 2024 Jan; 11 (1): 207 - 214.Journal ArticleAssociation Between Urologist Merit-Based Incentive Payment System Performance and Quality of Prostate Cancer Care.
DOI:10.1097/UPJ.0000000000000463 PMID: 37748132 -
Maganty A, Kaufman SR, Oerline MK, Faraj KS, Caram MEV, Shahinian VB, Hollenbeck BK. Cancer Med, 2023 Dec 26; 13 (1):Journal ArticleValue-based payment models and management of newly diagnosed prostate cancer.
DOI:10.1002/cam4.6810 PMID: 38146905 -
Skolarus TA, Forman J, Sparks JB, Metreger T, Hawley ST, Caram MV, Dossett L, Paniagua-Cruz A, Makarov DV, Leppert JT, Shelton JB, Stensland KD, Hollenbeck BK, Shahinian V, Sales AE, Wittmann DA. Implement Sci Commun, 2023 Mar 20; 4 (1): 31Journal ArticleCorrection: Learning from the "tail end" of de-implementation: the case of chemical castration for localized prostate cancer.
DOI:10.1186/s43058-023-00411-9 PMID: 36941664 -
Faraj KS, Kaufman SR, Herrel LA, Maganty A, Oerline M, Caram MEV, Shahinian VB, Hollenbeck BK. Cancer Med, 2023 Dec; 12 (24): 22325 - 22332.Journal ArticleThe immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer.
DOI:10.1002/cam4.6788 PMID: 38100144 -
Faraj KS, Kaufman SR, Herrel LA, Maganty A, Oerline M, Caram MEV, Shahinian VB, Hollenbeck BK. Urol Pract, 2023 Nov; 10 (6): 597 - 603.Journal ArticleAcquisition of Urology Practices by Private Equity Firms and Performance in the Merit-based Incentive Payment System.
DOI:10.1097/UPJ.0000000000000441 PMID: 37856709 -
Singhal U, Hollenbeck BK, Kaffenberger SD, Salami SS, George AK, Skolarus TA, Montgomery JS, Wittmann DA, Miller DC, Wei JT, Palapattu GS, Montie JE, Dunn RL, Morgan TM. J Urol, 2023 Nov; 210 (5): 771 - 777.Journal ArticleComparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice.
DOI:10.1097/JU.0000000000003646 PMID: 37566643 -
Herr DJ, Elliott DA, Duchesne G, Stensland KD, Caram MEV, Chapman C, Burns JA, Hollenbeck BK, Sparks JB, Shin C, Zaslavsky A, Tsodikov A, Skolarus TA. Cancer, 2023 Oct 15; 129 (20): 3326 - 3333.Journal ArticleOutcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system.
DOI:10.1002/cncr.34916 PMID: 37389814